BIO Common Stock · Transaction Nov 3, 2023 · Filed Dec 6, 2023 · Amount pending receipt enrichment
Bio-Rad Laboratories, Inc.Class A
Veridion Score
BETAHIGH CONF · 6/6 factorsComposite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Why is BIO moving today?
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
BIO overview
Related filings and maps
Congress activity in BIO
BIO Common Stock · Transaction Oct 26, 2023 · Filed Nov 8, 2023 · Amount pending receipt enrichment
BIO Common Stock · Transaction Oct 2, 2023 · Filed Nov 8, 2023 · Amount pending receipt enrichment
BIO · Transaction Sep 8, 2023 · Filed Oct 10, 2023 · $1,001 to $15,000
BIO Common Stock · Transaction Jun 29, 2023 · Filed Jul 11, 2023 · Amount pending receipt enrichment
BIO contract awards, year to date.
Public federal awards linked to this ticker.
BIO lobbying filings, year to date.
Registered lobbying filings matched to Bio-Rad Laboratories, Inc.Class A.
FORBES-TATE
FORBES-TATE
FORBES-TATE